FDA Adverse Event Injury Summary report: N

XIENCE PRIME EVEROLIMUS ELUTING CORONARY STENT SYSTEM

MDR report key: 3895378 · Received June 25, 2014

Report

Report Number
2024168-2014-04110
Event Type
Injury
Date Received
June 25, 2014
Date of Event
January 17, 2014
Report Date
June 5, 2014
Manufacturer
AV-TEMECULA-CT
Product Code
NIQ
PMA / PMN Number
P110019
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NL
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

(B)(4). INTIMAL DISSECTION IS LISTED IN THE XIENCE PRIME EVEROLIMUS ELUTING CORONARY STENT SYSTEMS INSTRUCTIONS FOR USE (IFU) AS A KNOWN PATIENT EFFECT OF CORONARY STENTING PROCEDURES. ALTHOUGH A CONCLUSIVE CAUSE FOR THE REPORTED PATIENT EFFECTS, AND THE RELATIONSHIP TO THE PRODUCT, IF ANY, CANNOT BE DETERMINED, THERE IS NO INDICATION OF A PRODUCT QUALITY DEFICIENCY WITH RESPECT TO MANUFACTURING, DESIGN OR LABELING.

Additional Manufacturer Narrative · 1

(B)(4). CONCOMITANT PRODUCTS: STENT: XIENCE PRIME (4.0X15MM, 3.5X23MM, 2.75X18MM, 3.0X28MM); OTHER: ASPIRIN, CLOPIDOGREL. THE STENT REMAINS IN THE PATIENT. INVESTIGATION IS NOT YET COMPLETE. A FOLLOW-UP REPORT WILL BE SUBMITTED WITH ALL ADDITIONAL RELEVANT INFORMATION.

Description of Event or Problem · 1

IT WAS REPORTED THAT ON (B)(6) 2014, THE PATIENT WAS HOSPITALIZED DUE TO UNSTABLE ANGINA. ON (B)(6) 2014, TROPONIN I REMAINED ELEVATED. ON (B)(6) 2014 DURING A DISTAL RIGHT CORONARY ARTERY (RCA) STENTING PROCEDURE, A DISSECTION WAS NOTED IN THE MID RCA. A 3.0X28MM XIENCE PRIME STENT WAS IMPLANTED, SUCCESSFULLY TREATING THE DISSECTION. DURING THIS PROCEDURE, INCLUDING THE STENT IN THE MID RCA, 6 XIENCE PRIME STENTS WERE IMPLANTED. ON 01/18/2014, TROPONIN I WAS NOTED TO BE ELEVATED AND THE PATIENT WAS DISCHARGED. THERE WAS NO ADDITIONAL INFORMATION PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
370269 XIENCE PRIME EVEROLIMUS ELUTING CORONARY STENT SYSTEM DRUG ELUTING CORONARY STENT SYSTEM NIQ AV-TEMECULA-CT 2051441

Patients

Seq Age Sex Outcome Treatment
1 82 YR Required Intervention